Cargando…
Therapeutic Targeting of c-Myc in T-Cell Acute Lymphoblastic Leukemia (T-ALL)
T-ALL patients treated with intensive chemotherapy achieve high rates of remission. However, frequent long-term toxicities and relapses into chemotherapy-refractory tumors constitute major clinical challenges which could be met by targeted therapies. c-MYC is a central oncogene in T-ALL, prompting t...
Autores principales: | Loosveld, Marie, Castellano, Rémy, Gon, Stéphanie, Goubard, Armelle, Crouzet, Thomas, Pouyet, Laurent, Prebet, Thomas, Vey, Norbert, Nadel, Bertrand, Collette, Yves, Payet-Bornet, Dominique |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4102800/ https://www.ncbi.nlm.nih.gov/pubmed/24930440 |
Ejemplares similares
-
Fit αβ T-cell receptor suppresses leukemogenesis of Pten-deficient thymocytes
por: Gon, Stéphanie, et al.
Publicado: (2018) -
MYC deficiency impairs the development of effector/memory T lymphocytes
por: Nozais, Mathis, et al.
Publicado: (2021) -
Calcium Signaling Is Impaired in PTEN-Deficient T Cell Acute Lymphoblastic Leukemia
por: Pankaew, Saran, et al.
Publicado: (2022) -
Immunomodulatory Drugs Exert Anti-Leukemia Effects in Acute Myeloid Leukemia by Direct and Immunostimulatory Activities
por: Le Roy, Aude, et al.
Publicado: (2018) -
Drug response profiling can predict response to ponatinib in a patient with t(1;9)(q24;q34)-associated B-cell acute lymphoblastic leukemia
por: Collette, Y, et al.
Publicado: (2015)